Barclays Maintains Equal-Weight on Minimed Group, Lowers Price Target to $20

Benzinga · 19h ago
Barclays analyst Christopher Pasquale maintains Minimed Group (NASDAQ:MMED) with a Equal-Weight and lowers the price target from $22 to $20.